(Les stocks de biotechnologies ont atteint un creux de 52 semaines le 20 novembre)
- Fresenius Medical Care AG et Cie (NYSE: FMS )
 - Adamas Pharmaceuticals Inc (NASDAQ: ADMS )
 - Akebia Therapeutics Inc (NASDAQ: AKBA )
 - Aquestive Therapeutics Inc (NASDAQ: AQST )
 - Cancer Genetics Inc (NASDAQ: CGIX) ) (a enregistré une baisse de ses revenus et une perte plus importante pour le troisième trimestre)
 - Celgene Corporation (NASDAQ: CELG) )
 - Cellectis SA (NASDAQ: CLLS )
 - Celsion Corporation (NASDAQ: CLSN) )
 - CTI BioPharma Corp (NASDAQ: CTIC) )
 - Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) )
 - CytomX Therapeutics Inc (NASDAQ: CTMX )
 - DURECT Corporation (NASDAQ: DRRX )
 - Endologix, Inc. (NASDAQ: ELGX )
 - Erytech Pharma SA (NASDAQ: ERYP )
 - Kala Pharmaceuticals Inc (NASDAQ: KALA )
 - Keryx Biopharmaceuticals (NASDAQ: KERX )
 - KITOV PHARMA LT / S ADR (NASDAQ: KTOV )
 - Kodiak Sciences Inc (NASDAQ: KOD )
 - Mersana Therapeutics Inc (NASDAQ: MRSN )
 - Mesoblast limité (NASDAQ: MESO )
 - Neos Therapeutics Inc (NASDAQ: NEOS )
 - Neovasc Inc (NASDAQ: NVCN )
 - Novan Inc (NASDAQ: NOVN )
 - OptiNose Inc (NASDAQ: OPTN )
 - PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS )
 - Revance Therapeutics Inc (NASDAQ: RVNC )
 - SCYNEXIS Inc (NASDAQ: SCYX )
 - Sutro Biopharma Inc (NASDAQ: STRO )
 - Teligent Inc (NASDAQ: TLGT )
 - Tenax Therapeutics Inc (NASDAQ: TENX )
 - Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) )
 
Aucun commentaire:
Enregistrer un commentaire